Hutchmed's (HKG:0013) ORPATHYS will continue to be included in the updated National Reimbursement Drug List effective Jan. 1, 2025, on the same terms, a Thursday bourse filing said.
ORPATHYS is used for the treatment of certain patients with non-small cell lung cancer with MET exon 14 skipping alterations.
ORPATHYS was first included in the list on March 1, 2023.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。